Table 5.
Subsequent treatments
| Subsequent treatment | Overall (N = 62) | % | Starting dose | Clinical response | ||||||||
| Afatinib 40 mg (N = 39) | % | Afatinib 30 mg (N = 23) | % | p-value | CR/PR/SD (N = 47) | % | PD/NA (N = 15) | % | p-value | |||
| Yes | 25 | 40.3% | 15 | 38.5% | 10 | 43.5% | 0.697 | 20 | 42.6% | 5 | 33.3% | 0.526 |
| No | 37 | 59.7% | 24 | 61.5% | 13 | 56.5% | 27 | 57.4% | 10 | 66.7% | ||
| Patients receiving subsequent treatment | Overall (n = 25) | % | Afatinib 40 mg (N = 39) | % | Afatinib 30 mg (N = 23) | % | p-value | CR/PR/SD (N = 47) | % | PD/NA (N = 15) | % | p-value |
| Chemotherapy | ||||||||||||
| Yes | 14 | 56.0% | 7 | 46.7% | 7 | 70.0% | 0.256 | 11 | 23.4% | 3 | 20.0% | 0.784 |
| No | 11 | 44.0% | 8 | 53.3% | 3 | 30.0% | 36 | 76.6% | 12 | 80.0% | ||
| TKI other than osimertinib | ||||||||||||
| Yes | 14 | 56.0% | 9 | 60.0% | 5 | 50.0% | 0.903 | 11 | 23.4% | 3 | 20.0% | 0.784 |
| No | 11 | 44.0% | 6 | 40.0% | 5 | 50.0% | 36 | 76.6% | 12 | 80.0% | ||
| Osimertinib | ||||||||||||
| Yes | 4 | 16.0% | 2 | 13.3% | 2 | 20.0% | 0.581 | 3 | 6.4% | 1 | 6.7% | 0.969 |
| No | 21 | 84.0% | 13 | 86.7% | 8 | 80.0% | 44 | 93.6% | 14 | 93.3% | ||
| Bevacizumab | ||||||||||||
| Yes | 3 | 12.0% | 2 | 13.3% | 1 | 10.0% | 0.89 | 3 | 6.4% | 0 | 0.0% | 0.316 |
| No | 22 | 88.0% | 13 | 86.7% | 9 | 90.0% | 44 | 93.6% | 15 | 100.0% | ||
| Immune checkpoint inhibitors | ||||||||||||
| Yes | 2 | 8.0% | 1 | 6.7% | 1 | 10.0% | 0.701 | 1 | 2.1% | 1 | 6.7% | 0.386 |
| No | 23 | 92.0% | 14 | 93.3% | 9 | 90.0% | 46 | 97.9% | 14 | 93.3% | ||
TKI tyrosine kinase inhibitor, CR complete response, PR partial response, SD stable disease